ZA979937B - Delayed delivery system for acid-sensitive drugs - Google Patents
Delayed delivery system for acid-sensitive drugsInfo
- Publication number
- ZA979937B ZA979937B ZA979937A ZA979937A ZA979937B ZA 979937 B ZA979937 B ZA 979937B ZA 979937 A ZA979937 A ZA 979937A ZA 979937 A ZA979937 A ZA 979937A ZA 979937 B ZA979937 B ZA 979937B
- Authority
- ZA
- South Africa
- Prior art keywords
- delivery system
- acid
- barrier
- omeprazole
- pulsatile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74098196A | 1996-11-06 | 1996-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA979937B true ZA979937B (en) | 1999-05-18 |
Family
ID=24978866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA979937A ZA979937B (en) | 1996-11-06 | 1997-11-05 | Delayed delivery system for acid-sensitive drugs |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0941074B1 (xx) |
AT (1) | ATE271379T1 (xx) |
AU (1) | AU5179898A (xx) |
DE (1) | DE69729950T2 (xx) |
NO (1) | NO992186L (xx) |
WO (1) | WO1998019668A1 (xx) |
ZA (1) | ZA979937B (xx) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2774288B1 (fr) | 1998-01-30 | 2001-09-07 | Ethypharm Sa | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
FR2793688B1 (fr) | 1999-05-21 | 2003-06-13 | Ethypharm Lab Prod Ethiques | Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques |
SE9902386D0 (sv) * | 1999-06-22 | 1999-06-22 | Astra Ab | New formulation |
US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
DE19959419A1 (de) | 1999-12-09 | 2001-06-21 | Ratiopharm Gmbh | Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung |
ES2244167T3 (es) * | 1999-12-16 | 2005-12-01 | Laboratorio Medinfar-Produtos Farmaceuticos, S.A. | Nuevas preparaciones farmaceuticas multiunitarias estables que contienen bencimidazoles sustituidos. |
US6500457B1 (en) * | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
ES2663873T3 (es) * | 2001-10-29 | 2018-04-17 | Massachusetts Institute Of Technology | Forma farmacéutica con perfil de liberación de orden cero fabricada por impresión tridimensional |
US8168170B2 (en) | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
CA2518780C (en) * | 2003-03-12 | 2014-05-13 | Takeda Pharmaceutical Company Limited | Drug composition having active ingredient adhered at high concentration to spherical core |
WO2005051362A2 (en) * | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
WO2005092297A2 (en) * | 2004-03-03 | 2005-10-06 | Teva Pharmaceutical Industries Ltd. | A stable pharmaceutical composition comprising an acid labile drug |
CA2570796A1 (en) * | 2004-06-15 | 2006-01-05 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations of benzimidazole compounds |
AR052225A1 (es) * | 2004-11-04 | 2007-03-07 | Astrazeneca Ab | Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones |
AR051654A1 (es) * | 2004-11-04 | 2007-01-31 | Astrazeneca Ab | Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones |
US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US7923449B2 (en) | 2005-10-29 | 2011-04-12 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
CN101389316A (zh) * | 2005-12-28 | 2009-03-18 | 武田药品工业株式会社 | 控制释放固体制剂 |
BRPI0620788A2 (pt) * | 2005-12-28 | 2011-11-22 | Takeda Pharmaceutical | preparação sólida |
ES2336719T3 (es) | 2006-06-30 | 2010-04-15 | Boehringer Ingelheim International Gmbh | Flibanserina para el tratamiento de la incontinencia urinaria y las enfermedades relacionadas. |
CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
CA2660476C (en) | 2006-08-14 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
CA2661613C (en) * | 2006-08-25 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
EP2124966B1 (en) | 2007-02-01 | 2015-09-09 | IAMS Europe B.V. | Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts |
UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
WO2009113090A2 (en) * | 2008-01-17 | 2009-09-17 | Alkem Laboratories Ltd. | Process for preparing an oral formulation of an acid-sensitive benzimidazole drug |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
CA2686480A1 (en) | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
MX9600857A (es) * | 1994-07-08 | 1997-06-28 | Astra Ab | Forma de dosificacion i en tabletas, con unidades multiples. |
-
1997
- 1997-11-05 EP EP97946676A patent/EP0941074B1/en not_active Expired - Lifetime
- 1997-11-05 AT AT97946676T patent/ATE271379T1/de not_active IP Right Cessation
- 1997-11-05 WO PCT/US1997/020851 patent/WO1998019668A1/en active IP Right Grant
- 1997-11-05 ZA ZA979937A patent/ZA979937B/xx unknown
- 1997-11-05 DE DE69729950T patent/DE69729950T2/de not_active Expired - Fee Related
- 1997-11-05 AU AU51798/98A patent/AU5179898A/en not_active Abandoned
-
1999
- 1999-05-05 NO NO992186A patent/NO992186L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0941074B1 (en) | 2004-07-21 |
NO992186D0 (no) | 1999-05-05 |
DE69729950D1 (de) | 2004-08-26 |
EP0941074A1 (en) | 1999-09-15 |
AU5179898A (en) | 1998-05-29 |
ATE271379T1 (de) | 2004-08-15 |
NO992186L (no) | 1999-05-05 |
DE69729950T2 (de) | 2005-07-28 |
WO1998019668A1 (en) | 1998-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA979937B (en) | Delayed delivery system for acid-sensitive drugs | |
EP0670718B1 (en) | Pulsatile particles drug delivery system | |
US6761895B2 (en) | Drug delivery system for averting pharmacokinetic drug interaction and method thereof | |
AU1488295A (en) | Pharmaceutical composition | |
NZ237516A (en) | Device for drug delivery to intestinal tract comprising a core of active ingredient together with osmotically activated expulsion agent and an outer coating containing a hydrophobic material to assist in delaying release | |
DE60021604D1 (de) | Gastroretentive pharmazeutische dosierungsformen mit gesteuerten abgaben | |
EP1207860A1 (en) | Controlled release pellet formulation | |
MX9500885A (es) | Preparacion farmaceutica para administracion oral. | |
NO20003640L (no) | Ny doseringsform | |
MXPA01003197A (es) | Suministro enterico y colonico utilizando capsulas de chpm. | |
CA2144094A1 (en) | Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract | |
SI9520049A (en) | Controlled-release dosage forms of azithromycin | |
EP1098635A1 (en) | Enteric coated pharmaceutical tablet and method of manufacturing | |
NO982302L (no) | Farmas°ytisk sammensetning | |
US5824341A (en) | Composition providing selective release of an active ingredient | |
MXPA05001243A (es) | Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion. | |
EP1217992A1 (en) | Coated solid dosage forms | |
AU736357B2 (en) | Controlled-release pharmaceutical preparation comprising an ACE inhibitor as active ingredient | |
WO2001078681A1 (fr) | Systeme d'administration de medicament empechant l'interaction pharmacocinetique entre les medicaments et procede correspondant | |
AU2009247712C1 (en) | Compositions and methods for inhibiting gastric acid secretion | |
US6074669A (en) | Controlled drug delivery system for diltiazem | |
WO2004041244A2 (en) | Oral extended release tablets and methods of making and using the same | |
EP4013401A1 (en) | Articles and methods for administration of therapeutic agents | |
JPH06256166A (ja) | 薬物放出制御製剤 | |
MX9703918A (es) | Procedimiento para preparar un producto farmaceutico reactivo para deteccion de desorden gastrointestinal causado por bacteria en el tracto gastrointestinal superior. |